These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 19014204)

  • 21. A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness.
    Anderson M; Naci H; Morrison D; Osipenko L; Mossialos E
    J Clin Epidemiol; 2019 Jan; 105():50-59. PubMed ID: 30236484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of quality of data submitted for NICE technology appraisals over two decades.
    Osipenko L; Ul-Hasan SA; Winberg D; Prudyus K; Kousta M; Rizoglou A; Rustignoli I; van der Maas L
    BMJ Open; 2024 Feb; 14(2):e074341. PubMed ID: 38351112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Has NICE been nice to cancer?
    Summerhayes M; Catchpole P
    Eur J Cancer; 2006 Nov; 42(17):2881-6. PubMed ID: 17070032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-sectional analysis of use of real-world data in single technology appraisals of oncological medicine by the National Institute for Health and Care Excellence in 2011-2021.
    Kang J; Cairns J
    BMJ Open; 2024 Mar; 14(3):e077297. PubMed ID: 38485485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.
    Pinto A; Naci H; Neez E; Mossialos E
    Value Health; 2020 Mar; 23(3):319-327. PubMed ID: 32197727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring uncertainty and use of real-world data in the National Institute for Health and Care Excellence single technology appraisals of targeted cancer therapy.
    Kang J; Cairns J
    BMC Cancer; 2022 Dec; 22(1):1268. PubMed ID: 36471259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. National Institute for Clinical Excellence (NICE): Is economic appraisal working?
    Towse A; Pritchard C
    Pharmacoeconomics; 2002; 20 Suppl 3():95-105. PubMed ID: 12457430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.
    Longworth L; Youn J; Bojke L; Palmer S; Griffin S; Spackman E; Claxton K
    Pharmacoeconomics; 2013 Feb; 31(2):137-49. PubMed ID: 23329429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of NICE technology appraisal in NHS rationing.
    Walker S; Palmer S; Sculpher M
    Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 10 years of NICE: still growing and still controversial.
    Littlejohns P; Garner S; Doyle N; Macbeth F; Barnett D; Longson C
    Lancet Oncol; 2009 Apr; 10(4):417-24. PubMed ID: 19341973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evaluation of the impact of NICE guidance on GP prescribing.
    Wathen B; Dean T
    Br J Gen Pract; 2004 Feb; 54(499):103-7. PubMed ID: 14965388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Appraisal of Novel Oncological Therapies by the Scottish Medicines Consortium and the National Institute for Health and Care Excellence: A Comparative Study of Six Years of Data.
    Taylor R
    Cureus; 2023 Dec; 15(12):e50560. PubMed ID: 38222244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NICE guidance in the Scottish context.
    Kohli H; Tannahill A
    Scott Med J; 2009 Feb; 54(1):35-8. PubMed ID: 19291935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Public funding of new cancer drugs: Is NICE getting nastier?
    Mason AR; Drummond MF
    Eur J Cancer; 2009 May; 45(7):1188-1192. PubMed ID: 19138512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales.
    Trowman R; Chung H; Longson C; Littlejohns P; Clark P
    Clin Cancer Res; 2011 Aug; 17(15):4930-5. PubMed ID: 21791636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Views of Directors of Public Health about NICE Appraisal Guidance: results of a postal survey. National Institute for Clinical Excellence.
    Davies E; Littlejohns P
    J Public Health Med; 2002 Dec; 24(4):319-25. PubMed ID: 12546211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of UK primary care databases in health technology assessments carried out by the National Institute for health and care excellence (NICE).
    Leahy TP; Ramagopalan S; Sammon C
    BMC Health Serv Res; 2020 Jul; 20(1):675. PubMed ID: 32698805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug assessment: UK style.
    Drug Ther Bull; 2013 Dec; 51(12):141-4. PubMed ID: 24336496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?
    Walley T
    CNS Drugs; 2004; 18(1):1-12. PubMed ID: 14731055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?
    Cowles E; Marsden G; Cole A; Devlin N
    Appl Health Econ Health Policy; 2017 Aug; 15(4):469-477. PubMed ID: 28130691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.